Literature DB >> 11940091

A patient with treatment-resistant schizophrenia and cytochrome P4502D6 gene duplication.

C Kawanishi1, T Furuno, I Kishida, T Matsumura, K Kosaka.   

Abstract

We describe a patient with treatment-resistant schizophrenia who had a duplication in the cytochrome P450IID6 (CYP2D6) gene. This severely ill 71-year-old-woman had responded poorly to several neuroleptics. Molecular genetic study revealed CYP2D6 gene duplication, which results in excessive activity of CYP2D6 that metabolizes various commonly used neuroleptics. The mutation may have contributed to treatment resistance in this case.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11940091     DOI： 10.1034/j.1399-0004.2002.610211.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN： 0009-9163            Impact factor:   4.438


  4 in total

1.  The association between CYP2D6 genotype and switching antipsychotic medication to clozapine.

Authors:  Jochem G Gregoor; Karen van der Weide; Jan van der Weide; Harold J G M van Megen; Antoine C G Egberts; Eibert R Heerdink
Journal:  Eur J Clin Pharmacol       Date:  2013-07-07       Impact factor: 2.953

2.  Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses.

Authors:  A A Parkhomenko; M S Zastrozhin; VYu Skryabin; V A Ivanchenko; S A Pozdniakov; V V Noskov; I A Zaytsev; N P Denisenko; K A Akmalova; E A Bryun; D A Sychev
Journal:  Psychopharmacol Bull       Date:  2022-06-27

3.  Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.

Authors:  Silvana Borges; Zeruesenay Desta; Yan Jin; Azzouz Faouzi; Jason D Robarge; Sanosh Philips; Santosh Philip; Anne Nguyen; Vered Stearns; Daniel Hayes; James M Rae; Todd C Skaar; David A Flockhart; Lang Li
Journal:  J Clin Pharmacol       Date:  2010-01-15       Impact factor: 3.126

4.  Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.

Authors:  Chiaki Kawanishi; Stefan Lundgren; Hans Agren; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-02       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.